Tryptamine Therapeutics (AU:TYP) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tryptamine Therapeutics has announced that their Phase 1b study of TRP-8803, an IV-infused psilocin formulation, has been deemed safe by the Safety Review Council. This milestone paves the way for further clinical trials, building on promising results from previous studies using their oral psilocybin treatment, TRP-8802. The company aims to advance its innovative psilocin-based therapies, targeting conditions with unmet medical needs.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.